# Netherton Syndrome FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/netherton-syndrome

> 6 upcoming FDA catalysts in netherton Syndrome: qrx003, 4% lotion (QNRX) on Dec 2026 to Mar 2027 (topline data readout); qrx003, 4% lotion (QNRX) on Dec 2026 to Mar 2027 (topline data readout); qrx003, 4% lotion (QNRX) on December 2026 (primary completion); qrx003, 4% lotion (QNRX) on December 2026 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 30, 2025 | [Qrx003-2% lotion primary completion](https://sec-api.dev/pdufa/qrx003-2-lotion) | QNRX | Netherton Syndrome | completed | "NCT05521438 (Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-12-30 (ACTUAL); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05521438)) |
| 2H 2026 | [Rapamycin topline data readout](https://sec-api.dev/pdufa/rapamycin) | QNRX | Netherton Syndrome | scheduled | "NDA approval in 2027, reporting topline data from two whole-body clinical trials for the treatment of Netherton Syndrome in the second half of 2026, initiating proof of concept clinical testing in the second half of 2026 in at least one clinical indication for Quoin's rapamycin topical lotion and dermal patch platforms, the Company's year-end cash position funding operations into 2027, and Quoin's products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/tm269662d1_ex99-1.htm)) |
| August 28, 2026 | [QYLEKI (QRX003) interim data readout](https://sec-api.dev/pdufa/qrx003) | QNRX | Netherton Syndrome | completed, positive | "August 28, 2026, Quoin reported positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465926123960/tm2629259d1_ex99-1.htm)) |
| Dec 2026 to Mar 2027 | [Qrx003, 4% lotion topline data readout](https://sec-api.dev/pdufa/qrx003-4-lotion) | QNRX | Netherton Syndrome | scheduled | "NCT05789056 (Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05789056)) |
| Dec 2026 to Mar 2027 | [Qrx003, 4% lotion topline data readout](https://sec-api.dev/pdufa/qrx003-4-lotion) | QNRX | Netherton Syndrome | scheduled | "NCT06953466 (Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06953466)) |
| December 2026 | [Qrx003, 4% lotion primary completion](https://sec-api.dev/pdufa/qrx003-4-lotion) | QNRX | Netherton Syndrome | scheduled | "NCT05789056 (Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05789056)) |
| December 2026 | [Qrx003, 4% lotion primary completion](https://sec-api.dev/pdufa/qrx003-4-lotion) | QNRX | Netherton Syndrome | scheduled | "NCT06953466 (Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06953466)) |
| January 2027 | [QYLEKI (QRX003) primary completion](https://sec-api.dev/pdufa/qrx003) | QNRX | Netherton Syndrome | scheduled | "NCT07538583 (Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07538583)) |
| Q2 2027 | [QYLEKI (QRX003) topline data readout](https://sec-api.dev/pdufa/qrx003) | QNRX | Netherton Syndrome | scheduled | "the potential receipt of up to approximately $19.2 million of additional gross proceeds upon the cash exercise of the ordinary warrants issued in the private placement; QRX003 as a potentially safe and effective treatment for Netherton Syndrome; completing recruitment of all 20 participants in the Phase 2/3 study of QRX003 in Netherton Syndrome by the end of 2026 and reporting topline data from that study in the second quarter of 2027; moving closer towards the Company's goal of delivering the first approved treatment for Netherton" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465926123960/tm2629259d1_ex99-1.htm)) |

## Drugs

- [Qrx003-2% lotion](https://sec-api.dev/pdufa/qrx003-2-lotion) (QNRX)
- [Rapamycin](https://sec-api.dev/pdufa/rapamycin) (PVLA)
- [QYLEKI (QRX003)](https://sec-api.dev/pdufa/qrx003) (QNRX)
- [Qrx003, 4% lotion](https://sec-api.dev/pdufa/qrx003-4-lotion) (QNRX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/netherton-syndrome.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Netherton Syndrome FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/netherton-syndrome

```bibtex
@misc{secapidev_indications_netherton_syndrome_20261116,
  title        = {Netherton Syndrome FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/netherton-syndrome}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_netherton_syndrome_20261116","title":"Netherton Syndrome FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/netherton-syndrome","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
